WA-SEAGEN
10.11.2022 13:01:34 CET | Business Wire | Press release
Seagen Inc. (Nasdaq: SGEN) today announced that its Board of Directors has appointed David R. Epstein as Chief Executive Officer (CEO) and a member of the Board of Directors. Mr. Epstein brings more than 30 years of experience in the biopharmaceutical industry, including more than 25 years at Novartis where he built its oncology business unit from initiation to second largest in the world and then served as CEO of Novartis Pharmaceuticals, a division of Novartis AG. More recently, he was executive partner at Flagship Pioneering. In addition, Seagen announced that Roger Dansey, M.D., who has served as Seagen’s Chief Medical Officer (CMO) since 2018 and as Interim CEO since May 2022, has been appointed President, Research and Development. In this new role, Dr. Dansey will continue to serve as CMO reporting to David.
“Following a comprehensive search process, the Board selected David to serve as Seagen’s next CEO. He shares Seagen’s belief that our future is bright as we continue to build world-class capabilities in order to develop and commercialize new innovative treatments that improve the lives of patients with cancer. David’s demonstrated ability to build and scale a global oncology business, his experience in both large multi-faceted organizations and small biotechnology startups, combined with deep oncology knowledge, provide the strategic and operational expertise needed to lead Seagen to the next level,” said Felix J. Baker, Ph.D., Chair of the Board. “We are extremely grateful for Roger’s successful leadership and dedication as interim CEO. We look forward to Roger being able to focus his efforts on further strengthening our early research efforts, as he has successfully done for development, and driving the innovative engine that has been the heart of Seagen to have an even greater impact on cancer patients in the future.”
Mr. Epstein said, “I have long admired Seagen as a leader in the development and commercialization of transformative cancer therapies. Seagen is a pioneer in antibody-drug conjugate (ADC) technology with a portfolio of four approved medicines, a diverse pipeline of promising programs, and a science-driven, patient-first culture. I am honored to become CEO and work with the experienced team to further deliver on Seagen’s mission to make a meaningful difference so that people who have been diagnosed with cancer can live better lives.”
“I welcome David to the Seagen team and look forward to working closely with him as we continue to bring forward novel ADCs and other targeted treatments for cancer patients,” said Dr. Dansey. “I am excited to bring my passion for science and innovation to my expanded role overseeing research and development as we continue to deliver on the full potential of our pipeline and programs.”
About David R. Epstein
David R. Epstein has more than 30 years of drug development, deal making, commercialization and people leadership experience on a global scale. Most recently, he was executive partner at Flagship Pioneering, a builder of breakthrough bioplatform companies. From 2010 to mid-2016 he served as CEO of Novartis Pharmaceuticals, a division of Novartis AG. Previously, David started and led Novartis’ Oncology and Molecular Diagnostic units. Over the course of his career, he led the development and commercialization of over 30 new molecular entities, including major breakthroughs such as Glivec, Tasigna, Gilenya, Cosentyx and Entresto. Mr. Epstein holds a B.S. Degree in Pharmacy from Rutgers University College of Pharmacy and an MBA in Finance and Marketing from the Columbia University Graduate School of Business.
About Roger Dansey, M.D.
Dr. Dansey joined Seagen as CMO in 2018, bringing extensive experience in cancer drug development. Previously, he was Therapeutic Area Head for Late-Stage Oncology at Merck & Co., Inc., where he was responsible for registration efforts for Keytruda (pembrolizumab) across multiple tumor types. Earlier in his career, Dr. Dansey was the Vice President of Oncology Clinical Research at Gilead Sciences and the Global Development Lead for Xgeva (denosumab) at Amgen, where he held multiple roles in oncology and hematology.
About Seagen
Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company’s marketed products and robust pipeline, visit and follow @SeagenGlobal on Twitter.
Forward-Looking Statements
Certain of the statements made in this press release are forward looking, such as those, among others, relating to the potential of Seagen’s pipeline and programs, and the company’s efforts to build world-class capabilities in order to develop and commercialize new innovative treatments and to bring forward novel ADCs and other targeted treatments for cancer patients. Factors that may cause such a difference include, without limitation, the difficulty and uncertainty of pharmaceutical product development, the risk of adverse events or safety signals, the inability to show sufficient activity in clinical trials and the possibility of adverse regulatory actions. More information about the risks and uncertainties faced by Seagen is contained under the caption “Risk Factors” included in the company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221110005224/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Midas Atlantic Partners, in Partnership With the Najafi Companies, Has Entered Into a Put Option Agreement With Sylvamo Relating to the Potential Acquisition of Its European Operations6.11.2026 12:04:00 CET | Press release
Sylvamo’s European operations include its uncoated freesheet paper mills in Saillat (France) and Nymölla (Sweden), as well as its forestry and supporting business operations across EuropeRevenues of approximately EUR 630 million for the fiscal year ended December 2025Transaction expected to close in the first quarter of 2027 once the required consultation processes are completed and regulatory approvals are obtained Midas Atlantic Partners (“Midas Atlantic”), in partnership with The Najafi Companies, has signed a put option agreement with Sylvamo Corporation (“Sylvamo”) relating to the potential acquisition of its European operations (the “Business”). The transaction comprises Sylvamo’s uncoated freesheet paper mills in Saillat and Nymölla, as well as its forestry and supporting business operations across Europe. Closing is expected in the first quarter of 2027, once the required consultation processes are completed and regulatory approvals are obtained. The Business is a leading Europ
Suzano Reports 36% Increase in Third Quarter Net Revenue Following Consolidation of Arbex6.11.2026 00:23:00 CET | Press release
Suzano (B3: SUZB3 / NYSE: SUZ) , the world’s largest pulp producer, announces its results for the third quarter of 2026 (3Q26), which for the first time include Arbex, the joint venture between Suzano and Kimberly-Clark established in July this year. Driven primarily by the consolidation of Arbex’s contribution, Suzano reported net revenue of BRL16.5 billion, an increase of 36% on the same period last year and a new quarterly record in the company’s 102-year history. Adjusted EBITDA totaled R$5.7 billion in 3Q26, up 9% on the same basis of comparison. Operating cash generation reached R$3.8 billion, an increase of 12%. Net income totaled R$2.1 billion. As announced following the completion of the transaction with Kimberly-Clark, Suzano holds a 51% equity interest in Arbex and will therefore fully consolidate the joint venture’s financial statements from this quarter onwards.1 “This quarter marks the beginning of a new phase for Suzano. With Arbex, we are now a broader business, both ge
Andersen Consulting styrker sine transformationskompetencer med Bakia Consulting5.11.2026 23:12:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for forretningstransformation gennem en samarbejdsaftale med Bakia Consulting, et firma, der har specialiseret sig i transformation af økonomifunktionen. Bakia Consulting har hovedkontor i Paris og kapacitet i Singapore og Hongkong og har hjulpet store virksomheder og finansielle institutioner med at gentænke deres økonomifunktioner, herunder driftsmodeller, organisationsstrukturer, processer og digitale systemer. Bakia Consulting kombinerer projektledelse og forandringsledelse og arbejder tæt sammen med kunderne om at udvikle løsninger og fastholde forandringer. Virksomheden rådgiver også om modeller for økonomisk og ikke-økonomisk styring, procesoptimering og digitale værktøjer. "Økonomifunktioner forventes at levere bedre indsigt, arbejde mere effektivt og tilpasse sig skiftende forretningsbehov – ofte samtidig," udtalte Romain Dubuisson, partner hos Bakia Consulting. "Vi arbejder tæt sammen med vores kunder om at udvikle løsninger,
iQmetrix Unveils Built-In Intelligence for Every Role in Telecom Commerce at Its 2026 Telecom Industry Address5.11.2026 22:39:00 CET | Press release
An all-new AI inventory agent, iQ Hub and iQ Pay for Back Office bring intelligence to every role. iQmetrix, the global provider of Intelligent Commerce Operating Systems for telecom, last week shared highlights from its 2026 Telecom Industry Address and Product Announcements, held virtually on Oct. 28 in two sessions, one for North American audiences and one for European audiences. The address was built around one theme: intelligence. Telecom commerce is moving from systems that record the business to systems that act on it, and the announcements put that intelligence in the hands of every role, from the sales associate at the counter, to the finance manager in the back office, to the corporate view leading the channel experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105003162/en/ "Right now telecom providers are competing in a race to the bottom on price that no one wins. The way out is intelligence. Not AI bo
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.11.2026 22:30:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to nine newly hired non-executive employees. The equity awards were granted on November 2, 2026, and consisted of options to purchase an aggregate of 59,275 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 28,200 shares. These options have an exercise price per share equal to $8.41, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom